XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.
S
S

Sage


Haberler

Sage Therapeutics falls after Biogen terminates tremor drug partnership

BUZZ-Sage Therapeutics falls after Biogen terminates tremor drug partnership ** Shares of drug developer Sage Therapeutics SAGE.O fall 1% to $6.95 premarket ** Company says partner Biogen BIIB.O has terminated a licensing deal for Sage's experimental drug to treat essential tremor, effective February 2025 ** Sage had discontinued development of the
B
S

SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program

BRIEF-SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program Sept 26 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES DISCONTINUATION OF THE COLLABORATION WITH BIOGEN ON THE SAGE-324 PROGRAM SAGE THERAPEUTICS INC - BIOGEN TERMINATES RIGHTS UNDER SAGE-324 PROGRAM SAGE THERAPEUTICS I
S

Incorrect research alert on Sage Therapeutics Inc withdrawn

ADVISORY-Incorrect research alert on Sage Therapeutics Inc withdrawn An alert on J.P. Morgan cutting its price target on Sage Therapeutics Inc SAGE.O is incorrect and has been withdrawn. The brokerage lowered its PT on Sage Group PLC, an unrelated company. For the correct research alert on Sage Group PLC, click here . STORY_NUMBER: FWN3L714D STORY_
S

U.S. CH Robinson Worldwide, Dayforce, Entegris

U.S. RESEARCH ROUNDUP-CH Robinson Worldwide, Dayforce, Entegris Aug 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CH Robinson Worldwide, Dayforce and Entegris, on Thursday. HIGHLIGHTS * CH Robinson Worldwide Inc CHRW.O : JP Morgan raises to overweight from neutral * Dayforce Inc DAY.N : Piper Sandler raises to overweight from neutral * Entegris Inc ENTG.O : Seaport Research Partners raises to buy from neutral * M
B
C
D
E
M
Q
S
V
A
C
D
E
L
T
P
W
A
B
C

SAGE Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

SAGE Therapeutics Inc reports results for the quarter ended in June - Earnings Summary SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.70​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-2.68. The mean expectation of twenty analysts for the quarter was for a loss of $1.66 per share.
S

SAGE Therapeutics Inc <SAGE.OQ> expected to post a loss of $1.66 a share - Earnings Preview

SAGE Therapeutics Inc expected to post a loss of $1.66 a share - Earnings Preview SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to show a rise in quarterly revenue when it reports results on July 31 for the period ending June 30 2024 The Cambridge Massachusetts-based company is expected to report a 258.2% increase in revenue to $8.848 million from $2.47 million a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
S

U.S. Edwards Lifesciences, National Bank Holdings, Sage Therapeutics

U.S. RESEARCH ROUNDUP-Edwards Lifesciences, National Bank Holdings, Sage Therapeutics July 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Edwards Lifesciences, National Bank Holdings and Sage Therapeutics, on Thursday. HIGHLIGHTS * Edwards Lifesciences Corp EW.N : JP Morgan cuts to neutral from overweight * National Bank Holdings Corp NBHC.N : Piper Sandler cuts to neutral from overweight * Sage Therapeutics Inc S
A
A
C
C
G
S
C
E
H
I
A
A
E
L

U.S. STOCKS Tesla, Lamb Weston, Blackstone Mortgage Trust

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq plummeted to a one-month low on Wednesday after Tesla and Alphabet disappointed with lackluster earnings, prompting investors to question if the Big Tech and AI-fueled 2024 equity rally was sustainable in the long run.
A
C
F
G
M
S
S
T
V
C
T
U
U
E
T
L
O

U.S. STOCKS FTAI Aviation, Check Point, Sage Therapeutics

BUZZ-U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Wednesday, with the tech-heavy Nasdaq leading declines after lackluster quarterly results from Tesla and Alphabet raised questions about the sustainability of the Big Tech and AI-led 2024 equity rally.
A
F
G
M
S
T
V
C
T
U
U
E
T
L
O

Sage shares decline on plans to scrap development of tremor drug

BUZZ-Sage shares decline on plans to scrap development of tremor drug Updates ** Shares of Sage Therapeutics SAGE.O fall ~ 1 7.5 % to $10.7 9 , its biggest one day loss pct since April ** Co, partner Biogen's BIIB.O oral experimental drug, SAGE-324, to treat essential tremors failed in a mid-stage study ** Co, BIIB do not plan to develop the drug f
B
S

Sage shares decline on plans to scrap development of tremor drug

BUZZ-Sage shares decline on plans to scrap development of tremor drug ** Shares of Sage Therapeutics SAGE.O fall 19% to $10.60 premarket ** Co, partner Biogen's BIIB.O oral experimental drug, SAGE-324, to treat essential tremors failed in a mid-stage study ** Co, BIIB do not plan to develop the drug further but may consider it for other potential c
B
S

Biogen and Sage to scrap neurological disorder drug development after trial failure

UPDATE 2-Biogen and Sage to scrap neurological disorder drug development after trial failure Adds share movement in paragraph 2, analyst comment in paragraph 4 July 24 (Reuters) - Biogen BIIB.O and Sage Therapeutics SAGE.O do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.
B
S

Sage Therapeutics And Biogen Announce Topline Results From Phase 2 Kinetic 2 Study Of 324 (BIIB124) For The Treatment Of Essential Tremor

BRIEF-Sage Therapeutics And Biogen Announce Topline Results From Phase 2 Kinetic 2 Study Of SAGE-324 (BIIB124) For The Treatment Of Essential Tremor July 24 (Reuters) - Sage Therapeutics SAGE.O SAGE THERAPEUTICS AND BIOGEN ANNOUNCE TOPLINE RESULTS FROM PHASE 2 KINETIC 2 STUDY OF SAGE-324 (BIIB124) FOR THE TREATMENT OF ESSENTIAL TREMOR SAGE THERAPEU
B
S

Biogen and Sage's neurological disorder drug fails in mid-stage trial

Biogen and Sage's neurological disorder drug fails in mid-stage trial July 24 (Reuters) - Biogen BIIB.O and Sage Therapeutics' SAGE.O neurological disorder drug failed in a mid-stage trial, the companies said on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar
B
S

U.S. Boston Beer Company, Inter Parfums, Netflix

U.S. RESEARCH ROUNDUP-Boston Beer Company, Inter Parfums, Netflix July 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Boston Beer Company, Inter Parfums and Netflix, on Friday. HIGHLIGHTS * Boston Beer Company Inc SAM.N : Piper Sandler cuts PT to $344 from $350 * Inter Parfums Inc IPAR.O : Jefferies raises to buy from hold * Netflix Inc NFLX.O : JP Morgan raises target price to $750 from $650 * Smurfit Westrock SW
C
N
N
P
S
D
E
C
C
E
M

U.S. Nvidia, Qualcomm, Tesla

U.S. RESEARCH ROUNDUP-Nvidia, Qualcomm, Tesla July 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Nvidia, Qualcomm and Tesla, on Wednesday. HIGHLIGHTS * Brighthouse Financial Inc BHF.O : Jefferies raises to buy from hold * Legalzoom.Com Inc LZ.O : JP Morgan cuts to neutral from overweight * Nvidia Corp NVDA.O : KeyBanc raises target price to $180 * Qualcomm Inc QCOM.O : KeyBanc raises target price to $225 * Tesla
A
A
A
A
A
C
G
M
M
N
P
Q
S
T
A
A
A
C
O
B
T
A
A
A
A
C
G
L
U



Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

Risk uyarısı: Sermayeniz risk altında. Kaldıraçlı ürünler herkese uygun olmayabilir. Lütfen Risk Bildirimi'mizi dikkate alın.